Collectively, these results link stromal myoferlin expression to increased tumor fibrosis (i.e., tumor desmoplasia) and suggest stromal myoferlin rather than cancer cell myoferlin as driver for tumor aggressiveness in PAAD patients. Here, MYOF is linked to pancreatic adenocarcinoma.